GENSCRIPT BIO(HK:01548) 智通财经网·2025-12-09 06:08Core Viewpoint - Kingsray Biotechnology (01548) experienced a significant decline of over 11%, trading at HKD 13.41 with a transaction volume of HKD 307 million, following a drop in the stock price of its affiliate Legend Biotech by over 7% [1] Group 1: Company Performance - Legend Biotech reported a total sales revenue of USD 1.332 billion for the first three quarters, with Q3 sales reaching USD 524 million [1] - The net loss for Legend Biotech in the first three quarters was USD 266 million, with a Q3 net loss of USD 40 million, indicating a substantial reduction in losses year-on-year and quarter-on-quarter [1] - Huatai Securities previously noted that Legend Biotech's losses are narrowing and the group's strategic vision is clear, suggesting a positive outlook for Kingsray Biotechnology's various business segments to achieve orderly profit growth and turnaround [1] Group 2: Clinical Data and Market Impact - Gilead Sciences' Kite Pharma presented new clinical data for its next-generation CAR-T therapy, anito-cel, at the 2025 American Society of Hematology (ASH) annual meeting, showing a total response rate of 96% and a complete response rate of 74%, while maintaining excellent safety [1]